EXC stock · FATE stock

EXC vs FATE · P/E 17, rev $24.26B vs rev $3.4M

Exelon Corporation (EXC) versus Fate Therapeutics Inc (FATE) — a side-by-side from cached financials, not a winner call.

Exelon Corporation (EXC) is a utilities - regulated electric company listed on NASDAQ.

Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.

Latest reported EXC revenue for 2025-12-31 was $24.26B. Net income was $2.77B. Revenue was up 5.3% from 2024-12-31 to 2025-12-31. EXC currently screens at market cap $47.33B and trailing P/E 16.8.

Latest reported FATE revenue for 2026-06-30 was $3.4M. Net income was -$61.4M. FATE currently screens at market cap $331.0M.

EXC currently screens at market cap $47.33B and trailing P/E 16.8. FATE currently screens at market cap $331.0M.

Not investment advice. Open the EXC and FATE stock pages for the full models.

Not investment advice.

Popular Stock Comparisons